Get the Stockscreener App
1.25
6.67%
-0.10
Revelation Biosciences Inc stock is traded at $1.25, with a volume of 71,512.
It is down -6.67% in the last 24 hours and down -13.70% over the past month.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
See More
Previous Close:
$1.35
Open:
$1.34
24h Volume:
71,512
Relative Volume:
0.12
Market Cap:
$4.65M
Revenue:
-
Net Income/Loss:
$-15.52M
P/E Ratio:
-0.0673
EPS:
-18.58
Net Cash Flow:
$-16.61M
1W Performance:
+1.61%
1M Performance:
-13.70%
6M Performance:
-83.59%
1Y Performance:
-90.74%
1-Day Range:
$1.20
$1.34
1-Week Range:
$1.20
$1.4276
52-Week Range:
$1.19
$14.92
Revelation Biosciences Inc Stock (REVB) Company Profile
Name
Revelation Biosciences Inc
Sector
Industry
Phone
650-800-3717
Address
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Compare REVB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
1.25 | 5.02M | 0 | -15.52M | -16.61M | -18.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.33 | 125.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.67 | 81.90B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
708.18 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.88 | 42.50B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
287.82 | 33.16B | 5.36B | 287.73M | 924.18M | 2.5229 |
Revelation Biosciences Inc Stock (REVB) Latest News
Decliners Report: What is the earnings history of Revelation Biosciences Inc Equity Warrant2026 Major Catalysts & High Accuracy Investment Signals - baoquankhu1.vn
Can Revelation Biosciences Inc. Equity Warrant stock beat analyst upgradesSwing Trade & Expert Curated Trade Ideas - Naître et grandir
Market Review: How does Revelation Biosciences Inc Equity Warrant compare to its peersPortfolio Update Summary & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Risk Analysis: Is Revelation Biosciences Inc Equity Warrant backed by strong institutional buyingJuly 2025 Spike Watch & Smart Allocation Stock Reports - baoquankhu1.vn
History Review: Will Revelation Biosciences Inc Equity Warrant benefit from green energy policiesJuly 2025 Weekly Recap & Weekly High Potential Stock Alerts - baoquankhu1.vn
Dividend Watch: Can Revelation Biosciences Inc beat the S P 500Quarterly Market Summary & Low Drawdown Investment Ideas - baoquankhu1.vn
REVB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Sheboygan Press
EPS Watch: Does Revelation Biosciences Inc Equity Warrant stock benefit from AI growthJuly 2025 Reactions & Community Driven Trade Alerts - baoquankhu1.vn
Weekly Recap: Is enGene Holdings Inc forming bullish engulfing patternsPrice Action & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Activity Recap: What is Revelation Biosciences Inc Equity Warrants valuation compared to sectorEarnings Trend Report & Real-Time Market Trend Scan - baoquankhu1.vn
REVB: 2026 Begins with Financial Picture in Good Shape - Research Tree
REVB Should I Buy - Intellectia AI
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 - newswire.com
Revelation Biosciences Q4 net loss widens - TradingView
Revelation Biosciences (REVB) cuts 2025 loss, extends cash runway into early 2027 - Stock Titan
Kidney drug Gemini advances at Revelation, cash runway into 2027 - Stock Titan
Decliners Report: What is the Moat Score of Revelation Biosciences Inc2025 Support & Resistance & High Accuracy Investment Signals - baoquankhu1.vn
EBITDA per share of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView
Revelation Biosciences (REVB) to Release Quarterly Earnings on Thursday - Defense World
Income Plays: Whats the beta of Revelation Biosciences Inc stockTrade Risk Summary & Verified Stock Trade Ideas - baoquankhu1.vn
Analyst Upgrade: What is the Moat Score of Revelation Biosciences IncPortfolio Return Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) - Beaver County Times
Can Revelation Biosciences Inc. stock beat market expectations this quarterWeekly Stock Summary & Weekly Watchlist for Hot Stocks - mfd.ru
Quarterly Risk: Can Revelation Biosciences Inc lead its sector in growthWatch List & Real-Time Buy Signal Notifications - baoquankhu1.vn
Aug Levels: What is the Moat Score of Revelation Biosciences IncRate Hike & Momentum Based Trading Ideas - baoquankhu1.vn
Portfolio Shifts: How does Revelation Biosciences Inc compare to its peersWeekly Market Outlook & Entry and Exit Point Strategies - baoquankhu1.vn
Bearish Setup: Whats the profit margin of Revelation Biosciences Inc Equity Warrant2025 Key Lessons & Real-Time Volume Spike Alerts - baoquankhu1.vn
How does Revelation Biosciences Inc. compare to its peersJuly 2025 Review & Fast Gain Stock Trading Tips - mfd.ru
Is Revelation Biosciences Inc. stock positioned for digital transformationTrade Risk Assessment & AI Forecasted Entry/Exit Points - mfd.ru
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds - Columbia Daily Tribune
What makes Revelation Biosciences Inc. stock attractive todayJuly 2025 Big Picture & High Return Trade Guides - mfd.ru
Why retail investors pile into Revelation Biosciences Inc. stockInsider Selling & Weekly Setup with ROI Potential - mfd.ru
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development - Lubbock Avalanche-Journal
What’s the RSI of Revelation Biosciences Inc. Equity Warrant stockMarket Risk Analysis & Technical Buy Zone Confirmation - mfd.ru
Can Revelation Biosciences Inc. deliver alphaJuly 2025 Reactions & Reliable Momentum Entry Alerts - mfd.ru
Will Revelation Biosciences Inc. stock gain from lower inflation2025 Key Highlights & Daily Market Momentum Tracking - mfd.ru
Warrant holders register 4.27M Revelation (Nasdaq: REVB) shares - Stock Titan
Breakout Zone: What are the risks of holding Revelation Biosciences IncJuly 2025 Fed Impact & Fast Entry Momentum Alerts - baoquankhu1.vn
Revelation Biosciences (REVB) Price Target Increased by 300.00% to 86.70 - Nasdaq
Fundamentals Check: What is Graf Global Corp Debt Equity Composite Unitss valuation compared to sectorJuly 2025 Breakouts & AI Driven Price Forecasts - baoquankhu1.vn
Buyback Watch: Is ETHE trading at a discountJuly 2025 Market Mood & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Revelation Biosciences Inc Stock (REVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):